Last reviewed · How we verify
AMDX2011P
At a glance
| Generic name | AMDX2011P |
|---|---|
| Sponsor | Amydis Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AMDX-2011P in Participants With Alzheimer's Disease (PHASE2)
- A Study of AMDX-2011P in Participants With CAA (PHASE2)
- Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy (PHASE1, PHASE2)
- A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMDX2011P CI brief — competitive landscape report
- AMDX2011P updates RSS · CI watch RSS
- Amydis Inc. portfolio CI